Company profile
SynDevRx, Inc.
Privately held: no public share price (Venture-backed clinical-stage biotech (Cambridge, MA) developing metabolic-hormone-targeted cancer therapies (lead: evexomostat/SDX-7320); private, Series C, no public listing found. Not present in the existing roster. Sources: https://clinicaltrials.gov/study/NCT05455619 ; https://api.gleif.org/api/v1/lei-records/2549000CDYS5YH6XDR52 ; https://api.gleif.org/api/v1/lei-records/984500EC7LEQEU100570 ; https://pitchbook.com/profiles/company/47291-50 ; https://syndevrx.com/about/board-of-directors/ Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Methionine aminopeptidase 2 (MetAP2, inhibitor) | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.